Zhongdong Zhao

USPTO Granted Patents = 32 (Patent Applications = 9)

CIPO Patents = 4 (Patent Applications = 2)

EPO Patents = 16 (Patent Applications = 16)

Average Co-Inventor Count = 12.6

ph-index = 10

Forward Citations = 256(Granted Patents)

Location History:

Guilford, CT (US) (2011 - 2019)
Bellevue, WA (US) (2017 - 2024)

Company Filing History:

15 out of 919

Gilead Sciences, Inc.

patents

11 out of 30

Gilead Connecticut, Inc.

Cgi Pharmaceuticals, Inc.

where one patent can have more than one assignee

Years Active: 2011-2025

Loading Chart...

32 patents (USPTO):Sort by Forward Citations

Abstract keywords

1. 12263163 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine as a Syk inhibitor (2025-04-01),

2. 12053462 - Quinoline derivatives (2024-08-06),

3. 11578069 - Compounds for inhibition of α4 β7 integrin (2023-02-14),

4. 11517570 - Crystalline succinate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2022-12-06),

5. 11224600 - Compounds for inhibition of alpha 4 beta 7 integrin (2022-01-18),

6. 11179383 - Compounds for inhibition of α4β7 integrin (2021-11-23),

7. 11174256 - Imidazopyridine derivatives (2021-11-16),

8. 11116760 - Quinoline derivatives (2021-09-14),

9. 10842803 - Imidazopyridines Syk inhibitors (2020-11-24),

10. 10828299 - Crystalline monomesylate salt of 6-(6-aminopyrazin-2-yl)-n-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine (2020-11-10),

11. 10344040 - Pyridone and aza-pyridone compounds and methods of use (2019-07-09),

12. 10342794 - Substituted imidazo[1,2-a]pyrazines as Syk inhibitors (2019-07-09),

13. 10253019 - Tank-binding kinase inhibitor compounds (2019-04-09),

14. 10092583 - Imidazopyridines Syk inhibitors (2018-10-09),

15. 10053469 - Pyridone and aza-pyridone compounds and methods of use (2018-08-21),

Certainly! Here is an article about inventor Zhongdong Zhao.

Title: Zhongdong Zhao: Pioneering Innovations in Pharmaceutical Compounds

Introduction:

In the realm of inventors driving breakthroughs in pharmaceutical compounds, Zhongdong Zhao stands as a notable figure. Hailing from Guilford, CT (US), Zhao's contributions have left a lasting impact on the field of medicine and therapy.

Latest Patents:

1. Compounds for Inhibition of α4 β7 Integrin: Zhao's patented compound of Formula (I) showcases his dedication to developing pharmaceutical compositions for treating inflammatory diseases effectively.

2. Crystalline Succinate Salt of 6-(6-aminopyrazin-2-yl)-N-(4-(4-(oxetan-3-yl)piperazin-1-yl)phenyl)imidazo[1,2-a]pyrazin-8-amine: This patent highlights Zhao's innovative approach as he explores Syk inhibitors for treating conditions like cancer and inflammatory ailments.

Career Highlights:

With an impressive portfolio of 30 patents, Zhao has demonstrated a consistent commitment to driving innovation in the pharmaceutical industry. His work reflects a deep understanding of molecular structures and their therapeutic applications.

Collaborations:

Throughout his career, Zhao has collaborated with esteemed professionals in the field. Noteworthy coworkers include Kevin S Currie and Peter A Blomgren. His tenure at Gilead Sciences, Inc. and Gilead Connecticut, Inc. exemplifies his dedication to advancing pharmaceutical research.

Conclusion:

In conclusion, Zhongdong Zhao's inventive spirit and strategic approach to developing pharmaceutical compounds underscore his position as a key player in the industry. His patents and collaborations attest to his significant contributions towards enhancing therapeutic interventions and improving healthcare outcomes.

This text is generated by artificial intelligence and may not be accurate.